市场调查报告书
商品编码
1401842
到 2030 年快速微生物检测市场预测:按产品、方法、应用和地区分類的全球分析Rapid Microbiology Testing Market Forecasts to 2030 - Global Analysis By Product (Instruments, Reagents and kits, Consumables and Other Products), Method, Application and By Geography |
根据 Stratistics MRC 的数据,2023 年全球快速微生物检测市场规模为 47 亿美元,预计在预测期内将以 10.8% 的复合年增长率成长,到 2030 年达到 97 亿美元。
微生物检测能够快速及早识别微生物带来的潜在健康威胁,即时监控关键控制点,优化生产工艺,提高产品安全性,并降低整体品质程序的成本。快速微生物检测是一种用于药物开发、研究和其他诊断的技术。快速微生物检测用于快速诊断感染疾病。这有助于治疗下呼吸道感染疾病。与传统的基于文化的测试相比,这些测试提供了更快速的观察。
据PHAC称,2021年加拿大报告了超过225,000例法定感染疾病病例,包括性行为感染、食物中毒和呼吸道感染疾病。
感染疾病增加
包括疟疾、爱滋病毒、肺炎和肺结核在内的感染疾病正变得越来越常见。提高人们对爱滋病毒、癌症、结核病和肺炎等感染疾病认识的计划很普及,以促进早期发现和预防性护理,从而获得更好的治疗结果。这些疾病日益增加的全球负担可能会导致在整个预测期内对快速微生物治疗的需求显着增加。
医疗服务不足
低度开发国家的许多人缺乏医疗设施和保持健康所需的资讯。此外,一个主要的公共卫生障碍是缺乏资金,这加剧了感染疾病问题,这是一个严重的公共卫生问题。此外,大多数贫穷国家的卫生系统难以留住合格的专业人员,且难以提供快速微生物检测等优质卫生服务。这是市场拓展的障碍。
人们对食品安全的担忧日益加深
食品由植物和动物组成,通常含有多种微生物。在阶段和阶段过程中,食品会与自然产生的微生物接触并可能受到污染。为了确保食品和饮料部门向客户提供最高水准的产品安全和质量,监管机构定期更新食品安全法。因此,预计市场在整个预测期内都会成长。
设备成本高
与传统方法相比,快速程序可能会导致更高的初始设备设定成本。对于融资短缺的小型实验室和研究机构来说,这可能是个绊脚石。在快速技术中使用的其他消耗品中,检测套组和墨盒可能很昂贵。这些成本随着时间的推移而积累,最终可能超过与传统技术相关的成本。这些都阻碍了市场的拓展。
在大流行的早期阶段,无法进行特定的诊断测试来检测患者的疾病。最初,使用了替代诊断测试,但效果不是很好。特定的 COVID-19 诊断测试的缺乏为诊断製造商推出诊断套件提供了有利可图的机会。各国各大企业和新兴企业纷纷利用这项契机,不仅在国内,而且在全球市场推出诊断套件。透过利用诊断测试需求带来的机会,这些公司可以比其他诊断製造商获得优势,从而帮助他们在这场危机期间保持收益。Masu。
预计在预测期内基于电池组件的细分市场将是最大的
由于对微生物病原体的检测更加准确和灵敏,基于细胞成分的细分市场预计将在预测期内增长,这对于有效治疗和控制感染疾病至关重要。基于细胞成分的快速微生物检测可用于诊断许多严重疾病,包括食品感染疾病、医疗保健相关感染疾病和感染疾病。由于对这些疾病快速、准确的诊断测试的需求不断增加,预计市场将继续扩大。
预计临床诊断检测领域在预测期内复合年增长率最高
预计临床诊断测试领域在预测期内复合年增长率最高。临床诊断中采用快速微生物检测方法来识别和分类临床检体(例如血液、尿液和痰)中的感染性细菌。随着感染疾病变得越来越普遍,临床实务中越来越需要快速微生物检测方法。测试方法的技术进步正在提高测试的准确性和效率,从而推动其在整个行业临床诊断中的使用。
预计北美在预测期内将占据最大的市场占有率。该市场受到多种因素的推动,包括对药物和疫苗开发的日益重视、生物技术和药物研究的最新研究和发展,以及该国存在提供广泛微生物检测产品的多家供应商。因素。因此,该地区接受微生物检测的关键因素是对药品生产的日益关注。
预计亚太地区在预测期内将维持最高的复合年增长率。各个领域对快速结果的需求、更严格的立法以及对微生物安全重要性的更深入理解都有助于提高快速微生物检测程序的接受度。持续的技术改进促进了更快、更准确的微生物检测技术的发展。
According to Stratistics MRC, the Global Rapid Microbiology Testing Market is accounted for $4.7 billion in 2023 and is expected to reach $9.7 billion by 2030 growing at a CAGR of 10.8% during the forecast period. Microbiology testing is done quickly to identify potential health threats from microorganisms early on, monitor vital control points in real time, optimize production processes, boost product safety, and lower overall quality procedure costs. Rapid microbiological testing is a technology used in drug development, research, and other diagnostic applications. Rapid microbiological testing is used to help diagnose infections like TB and malaria quickly. This aids in the treatment of lower respiratory tract infections. When compared to conventional testing based on culture, these tests yield speedier findings.
According to the PHAC, there were over 225,000 reported cases of notifiable infectious diseases in Canada in 2021, including sexually transmitted infections, foodborne illnesses, and respiratory infections.
Rising rates of infectious illnesses
Infectious illnesses including malaria, HIV, pneumonia, and TB are becoming more common. Programs to raise awareness of infectious diseases including HIV, cancer, TB, and pneumonia have become more prevalent in an effort to promote early detection and preventative healthcare, which can lead to better treatment outcomes. The increased global burden of these disorders will probably result in a significant rise in demand for fast microbiological procedures throughout the forecast period.
Inadequate healthcare services
Many individuals in underdeveloped nations lack access to healthcare facilities and the necessary information to maintain their health. Additionally, a major barrier to public health is a lack of funding, which exacerbates the problem of infectious illnesses, which is a serious public health concern. Furthermore, the majority of poor nations' healthcare systems struggle to staff with qualified professionals, which makes it challenging for them to offer access to high-quality medical services like quick microbiological testing. This reflects the impediment to the market's expansion.
Increasing concerns about food safety
Food items consist of both plants and animals, and they typically include a range of microbes. During the production and consumption stages, food may come into touch with natural source microbes and get contaminated. To guarantee that the food and beverage sectors provide customers with the highest level of product safety and quality, regulatory bodies regularly update food safety laws. As a result, growth in the market is anticipated throughout the forecast period.
High equipment cost
Rapid procedures may incur greater initial setup expenses for equipment compared to older approaches. For smaller labs or institutions with tighter funds, this might be a hindrance. Test kits and cartridges, among other consumables used in quick techniques, can be costly. These expenses have the potential to accumulate over time and eventually outweigh those related to conventional techniques. These are the things impeding the market's expansion.
At the early phase of pandemic, there was no availability of specific diagnostic tests to detect the disease in patients. Alternative diagnostic tests were used initially but were not much effective. This unavailability of specific COVID-19 diagnostic tests presented lucrative opportunities for diagnostic manufacturers to introduce their diagnostic kits. Many leading players as well as some start-ups from various countries utilized this opportunity and introduced diagnostics kits into local as well as global market. These players achieved edge over other diagnostics players capitalizing the opportunity from demand for diagnostic tests, which, in turn, helps them in maintaining their revenues in such a crisis.
The cellular component based segment is expected to be the largest during the forecast period
The cellular component based segment is expected to be the largest during the forecast period, owing to more accurate and more sensitive detection of microbial pathogens, which is crucial for effective treatment and control of infectious diseases. Rapid microbiological testing based on cellular components is used to diagnose a number of serious conditions, such as foodborne infections, infections linked to healthcare, and infectious diseases. The market is anticipated to keep expanding in the future due to the growing need for quicker and more precise diagnostic tests for these illnesses.
The clinical diagnosis testing segment is expected to have the highest CAGR during the forecast period
The clinical diagnosis testing segment is expected to have the highest CAGR during the forecast period. In order to identify and categorize infectious bacteria in clinical samples including blood, urine, and sputum, rapid microbiology testing methods are employed in clinical diagnosis. Rapid microbiological testing methods are becoming more and more necessary in clinical settings as infectious illnesses become more common. Technological advancements in testing methodologies have improved testing accuracy and efficiency, hence encouraging their usage in clinical diagnostics across the industry.
North America is projected to hold the largest market share during the forecast period. The market is expanding due to a number of factors, including the increased emphasis on the creation of drugs and vaccines, recent developments in biotechnology and pharmaceutical research, and the availability of several vendors in the nation that provide a broad selection of microbial testing products. Thus, a key factor in the region's acceptance of microbiological testing has been the increased focus on medication manufacture.
Asia Pacific is projected to hold the highest CAGR over the forecast period. The demand for quicker results in a variety of sectors, stricter laws, and a growing understanding of the significance of microbiological safety have all contributed to the growing acceptance of rapid microbiology testing procedures. The development of more quick and precise microbiological testing techniques is facilitated by ongoing technological improvements.
Some of the key players in Rapid Microbiology Testing market include Thermo Fisher Scientific Inc., Don Whitley Scientific Limited, Mocon, Inc, Becton, Dickinson, and Company, Danaher Corporation, Merck KGaA, Rapid Micro Biosystems Inc., Vivione Biosciences LLC, Abbott Laboratories, Inc., Quidel Corporation, Sartorius AG, Biomerieux SA, NEOGEN Corporation and Microgenetics.
In September 2022, Microgenetics developed a Rapid Microbial Method with a six-hour turnaround time. This crucial stage is costing many businesses time and resources because compendial methods of microbial contamination tests have a turnaround time of 14 days, and even faster technologies take about 4 days.
In August 2022, Together, BD and Accelerate Diagnostics are fighting antibiotic resistance. Through a global commercial partnership, BD will make available Accelerate's rapid testing solution for antibiotic resistance and susceptibility, which provides results in hours as opposed to one to two days, as is the case with some conventional laboratory techniques.